Glioblastomamultiforme (GBM) is one of themost aggressive human tumorswith apoor prognosis. Current standard treatment includes chemotherapy with the DNA-alkylating agent temozolomide concomitant with surgical resection and/or irradiation.However, anumber of cases are resistant to temozolomide-inducedDNA damage due to elevated expression of the DNA repair enzyme O-methylguanine-DNA methyltransf...

PURPOSE To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. EXPERIMENTAL DESIGN This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib...

INTRODUCTION Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy. CASE REPORT We report the case of a 56 year old woman presenting with alveolo-interstitial pneumonia after treatment with Temozolomide. Initially she received induction treatment with Temozolomide and concomitant radiotherapy for bifocal high grade glioblastoma. A month la...

Temozolomide (TMZ), an alkylating agent, is widely used for treating high-grade gliomas and has emerged as a treatment option for primary central nervous system lymphoma (PCNSL) because of its good penetration of the blood-brain barrier (BBB) and mild toxicity profile. To our knowledge, the role of temozolomide in the treatment of lymphoma was confined to PCNSL and its role in lymphoma central ...

Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. Temozolomide frequently produces profound lymphopenia. We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature. Narrow monitoring with cytomegalovirus antigenem...

BACKGROUND Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT). This suggests that additional factors hamper temozolomide cytotoxicity. We aimed to confirm first that temozolomide is a target for the multidrug resistance transporter MDR1/ABCB1 and second ...

Although temozolomide has shown clinical activity against neuroblastoma, this activity is likely limited by the DNA repair enzyme O-methylguanine DNA methyltransferase (MGMT). We hypothesized that IFN-B could sensitize neuroblastoma cells to the cytotoxic effects of temozolomide through its ability to down-regulate MGMT expression. In vitro proliferation of three neuroblastoma cell lines treate...

objective(s):p in vitro chemosensitivity and resistance assays (csras) are a promising tool for personalized treatment of glioblastoma multiform (gbm). these assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. we aimed to assess the feasibility and validity of utilizing stereotactic biopsies of gbm in csras. materials and methods: single...

INTRODUCTION We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be very low, and very rarely are such cases reported. CASE PRESENTATION A 26-year-old Pakistani man who was treated for glioblastoma with temozol...

Temozolomide is an oral alkylating agent shown to have modest efficacy in the treatment of glioblastoma multiforme. Tumor necrosis factor (TNF) is a polypeptide cytokine with synergistic antitumor activity in combination therapy with alkylating agents. We investigated the combined use of Ad.Egr-TNF, a replication-defective adenoviral vector encoding the cDNA for TNFunder the control of chemo-in...